XoNovo Overview
- Year Founded
-
2013
- Status
-
Out of Business
- Latest Deal Type
-
Out of Business
XoNovo General Information
Description
Developer of technologies for the treatment of neurodegenerative diseases. The company engages in the development of small-molecule therapeutics for preventing the progressive loss of neuronal function across multiple neurodegenerative diseases, enabling physicians with selective modulation of autophagy and axonal transport machinery in neurons.
Contact Information
Corporate Office
- Ilan Ramon Street 2
- Ness Ziona
- Israel
Corporate Office
- Ilan Ramon Street 2
- Ness Ziona
- Israel
XoNovo Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Out of Business | 01-Sep-2019 | Completed | Out of Business | |||
| 1. Accelerator/Incubator | 12-Jan-2015 | Completed | Startup |
XoNovo Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
XoNovo FAQs
-
When was XoNovo founded?
XoNovo was founded in 2013.
-
Who is the founder of XoNovo?
Kenneth Hensley Ph.D, Ofir Levi Ph.D, and Rafi Gidron Ph.D are the founders of XoNovo.
-
Where is XoNovo headquartered?
XoNovo is headquartered in Ness Ziona, Israel.
-
What industry is XoNovo in?
XoNovo’s primary industry is Drug Discovery.
-
Is XoNovo a private or public company?
XoNovo is a Private company.
-
What is XoNovo’s current revenue?
The current revenue for XoNovo is 00000.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
